Vancouver, BC – May 1st, 2018 – Innovative Targeting Solutions Inc., (ITS) the global leader in the discovery and optimization of antibodies, today announced a research collaboration with Sanofi. The collaboration uses Innovative Targeting Solutions’ proprietary HuTARG platform to discover novel first-in-class antibody therapeutic candidates. The HuTARG platform, a first-in-class, protein engineering platform, is able to generate large repertoires of fully human antibodies or other protein-based drug modalities, in a mammalian cell host for the first time. This novel advancement allows for interrogation of billions of unique drug candidates directly for functional activity, while at the same time not imposing any restrictions on the types of proteins scaffolds being screened.
“We are delighted to establish a strategic collaboration with the exceptional teams at Sanofi to advance our revolutionary protein engineering platform,” Paul Kang, Chief Scientific Officer of Innovative Targeting Solutions. “Innovative Targeting Solutions’ HuTARG platform allows ITS and its collaborators to make first-in-class molecules by directly sifting through billions of drug candidates for the desired drug activity. This screening breadth is well beyond the capabilities of any other drug discovery technology.”
Details of the collaboration and financial terms are not being disclosed. This marks Innovative Targeting Solutions’ 7th pharma/biotech collaboration.
About Innovative Targeting Solutions Inc. Founded in 2008, Innovative Targeting Solutions Inc. is a privately-held company that has developed a next generation protein engineering platform for the generation of fully human antibody and T cell receptor based therapeutics using its proprietary HuTARG technology. The HuTARG technology is a fully mammalian technology that generates diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information, visit innovativetargeting.com
Hill + Knowlton Strategies